Inovio Pharmaceuticals (INO) Other Non-Current Assets (2010 - 2026)
Inovio Pharmaceuticals (INO) posted Other Non-Current Assets of $2.0 million for Q1 2026, little changed sequentially from $2.0 million in Q4 2025, and up 1.66% YoY from $2.0 million in Q1 2025.
Inovio Pharmaceuticals (INO) Other Non-Current Assets (2010 - 2026) Analysis & Trends
Inovio Pharmaceuticals has reported Other Non-Current Assets for 17 years, with the latest figure at $2.0 million in Q1 2026.
- Quarterly Other Non-Current Assets rose 1.66% year-over-year to $2.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 million (up 1.66% YoY) and the FY2025 annual result came in at $2.0 million, up 1.66% from the prior year.
- Other Non-Current Assets held at $2.0 million in Q1 2026 per INO's latest filing, from $2.0 million in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $2.0 million in Q2 2025 and troughed at $566415.0 in Q3 2024.
- A 5-year average of $1.2 million and a median of $701986.0 in 2022 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2022 and 2025: Other Non-Current Assets slumped 95.08% in 2022, then soared 255.3% in 2025.
- Over 5 years, Other Non-Current Assets stood at $684044.0 in 2022, then dropped by 11.51% to $605315.0 in 2023, then soared by 227.05% to $2.0 million in 2024, then gained by 1.66% to $2.0 million in 2025, then changed by 0.0% to $2.0 million in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $2.0 million, $2.0 million, and $2.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Inovio Pharmaceuticals | 96.32 Mn | 96.32 Mn | - | 1.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.92 Mn |
| Mar 31, 2026 | 2.01 Mn |
| Dec 31, 2025 | 2.01 Mn |
| Sep 30, 2025 | 2.01 Mn |
| Jun 30, 2025 | 2.01 Mn |
| Mar 31, 2025 | 1.98 Mn |
| Dec 31, 2024 | 1.98 Mn |
| Sep 30, 2024 | 566,415.00 |
| Jun 30, 2024 | 585,915.00 |
| Mar 31, 2024 | 605,315.00 |
| Dec 31, 2023 | 605,315.00 |
| Sep 30, 2023 | 605,315.00 |
| Jun 30, 2023 | 666,890.00 |
| Mar 31, 2023 | 652,517.00 |
| Dec 31, 2022 | 684,044.00 |
| Sep 30, 2022 | 701,986.00 |
| Jun 30, 2022 | 770,144.00 |
| Mar 31, 2022 | 1.27 Mn |
| Dec 31, 2021 | 1.43 Mn |
| Sep 30, 2021 | 1.76 Mn |